Immuno-Biological Laboratories

Basic Information

Stock Code
4570
Industry
Pharmaceuticals
Category Detail
Biotechnology & Pharmaceuticals
Prefecture
Gunma Prefecture
Establishment Year
September 1982
Listing Year
March 2007
Official Website
https://www.ibl-japan.co.jp/
TSE Information
TSE Information
Yahoo! Finance
Yahoo! Finance
Other Companies
Towns, SecureVe, Atect, Eiken Chemical, Kainos, Mizuho Medy, Delta-Fly, Jiban HD, Sysmex

Overview

Immuno-Biological Laboratories is a pharmaceutical manufacturer founded in 1982, with strengths in antibody reagent development and providing innovative products utilizing recombinant gene technology as a leading industry player.

Current Situation

Immuno-Biological Laboratories has secured stable revenue with consolidated sales of approximately 700 million yen in 2023. Its main business is the research, development, manufacturing, and sales of antibody reagents, strengthening competitiveness in the medical reagent market. The company has succeeded in producing advanced pharmaceutical raw materials such as human fibrinogen using recombinant silkworm technology. In 2016, it installed a GMP-compliant pilot plant for thorough quality management. Focusing on R&D investment, it aims to create innovative bio-products in the 2020s. From a sustainability perspective, it addresses environmental impact reduction and local community contributions. Moving forward, it will respond to domestic and international bio-pharmaceutical market expansion by strengthening core technologies and diversifying business areas. Incorporating the latest personnel and business development information, it targets establishing its position as a growth company in the medium to long term.

Trivia

Interesting Facts

  • World's first company to produce human fibrinogen using recombinant silkworms
  • Started in Chiyoda-ku, Tokyo, now headquartered in Fujioka City, Gunma Prefecture
  • Mid-sized bio company with capital exceeding 1.8 billion yen
  • Subsidiary Skylight Biotech supports R&D
  • High expertise in antibody technology in the medical reagent market
  • Expanded GMP-compliant manufacturing facilities in 2016 to strengthen quality control
  • Corporate logo using IBL abbreviation contributes to global recognition
  • Diversified management including limited cosmetics base material supply
  • Small sales scale but attacking niche markets with proprietary technology
  • Centered on a small elite team of technical specialists
  • Maintains close long-term relationships with medical and research institutions
  • Holds numerous patents in recombinant gene technology field
  • Gains high trust from domestic pharmaceutical-related companies despite small scale
  • Research reagent market is also an important customer segment beyond pharmaceuticals
  • Active joint research with universities as an R&D-oriented company

Hidden Connections

  • Recombinant silkworm technology jointly developed with major domestic university research teams, strong academic ties
  • Subsidiary entered cosmetics raw material market, developing collaborations with beauty-related companies
  • Rich track record in providing custom reagents for specific medical institutions
  • Strengths in regulatory compliance in genetic engineering field, established trust with government
  • Actively participates in local Gunma Prefecture industry-academia-government collaboration projects, contributing to regional industry development
  • Forms partnerships with several leading domestic companies in medical diagnostic reagents
  • Founder's family listed as shareholders, contributing to management stability
  • GMP-compliant manufacturing technology enables high-precision services despite small scale

Future Outlook

Growth Drivers

  • New product development through expanded application of recombinant technology
  • Increasing market needs for high-sensitivity antibody reagents
  • Expanded technology transfer to cosmetics raw materials market
  • Growing demand for medical reagents domestically and internationally
  • Trust building through strengthened GMP-compliant manufacturing
  • Increasing demand for R&D support services
  • Entry into bio drug discovery-related fields
  • Strengthened research base through regional collaboration
  • Development of new customer segments and sales channel expansion
  • Efforts in sustainable technology development

Strategic Goals

  • 20% improvement in recombinant product production efficiency
  • Achieve sales of approximately 1.5 billion yen
  • Diversification of sales channels domestically and internationally
  • Expansion of new antibody reagent product lineup
  • Establishment of sustainable production system through environmental impact reduction
  • Enhancement of employee R&D capabilities and recruitment expansion
  • Pursuit of business synergies through subsidiary collaboration
  • Increase ratio of cosmetics raw materials business as new market
  • Active acquisition and value maximization of technology patents
  • Enhanced brand value through collaboration with local communities

Business Segments

Medical Reagent Supply

Overview
Provides high-quality reagents and test kits for medical and research use, contributing to improved testing accuracy.
Competitiveness
High-purity product development utilizing recombinant silkworm technology
Customers
  • Hospital laboratories
  • Clinical testing facilities
  • Medical device manufacturers
  • Pharmaceutical companies
  • University research institutions
  • Public research institutes
  • Testing outsourcing facilities
  • University hospitals
  • Public health laboratories
  • Bio ventures
Products
  • Antibody reagents
  • Immunoassay kits
  • Diagnostic reagents
  • Recombinant proteins
  • Enzyme immunoassay reagents
  • Immunochromatographic reagents
  • Biomarker test kits
  • Clinical research reagents
  • Molecular diagnostic reagents
  • Standards and controls

Cosmetics Material Supply

Overview
Stably supplies high-function cosmetics raw materials, supporting trends in the beauty market.
Competitiveness
Balance of safety and functionality through proprietary bio-technology
Customers
  • Cosmetics manufacturers
  • OEM manufacturers
  • Beauty clinics
  • Raw material traders
  • Drugstore chains
  • Mail-order businesses
  • Esthetic salons
  • Agents
  • SPA operators
  • Specialty store chains
Products
  • Moisturizing ingredients
  • Antioxidant ingredients
  • Functional ingredients
  • Serum raw materials
  • Cosmetics bases
  • Fragrances
  • Surfactants
  • Anti-inflammatory ingredients
  • Photoaging prevention ingredients
  • Non-chemical raw materials

R&D Support Services

Overview
Provides diverse services to support customer R&D, contributing to technological innovation.
Competitiveness
Powerful integration of antibody and recombinant gene technologies
Customers
  • Bio ventures
  • University labs
  • Pharmaceutical companies
  • Medical institutions
  • Public research institutes
  • Technology development companies
  • Bio-related corporations
  • Testing businesses
  • Analytical institutions
  • Graduate research
Products
  • Antibody production services
  • Reagent development consulting
  • Technology transfer support
  • Biomarker discovery support
  • Contract analysis
  • Cell culture reagents
  • New reagent development outsourcing
  • Quality management support
  • Gene modification technology support
  • Protocol development

OEM and Contract Manufacturing

Overview
Provides OEM products tailored to customer needs using advanced GMP-compliant manufacturing technology.
Competitiveness
High-quality GMP manufacturing system and technical support capabilities
Customers
  • Pharmaceutical manufacturers
  • Cosmetics companies
  • Diagnostic reagent manufacturers
  • Bio companies
  • Venture companies
  • Research institutions
  • Manufacturing outsourcing services
  • Development-stage companies
  • Sales channel expansion companies
  • Domestic and international trading companies
Products
  • Antibody reagent OEM
  • Cosmetics contract manufacturing
  • Test kit manufacturing
  • GMP-compliant manufacturing
  • Recombinant protein manufacturing
  • Bio preparations
  • Culture equipment operation
  • Quality testing services
  • Product packaging services
  • Technical support

Competitive Advantage

Strengths

  • High antibody production technology capabilities
  • Uniqueness of recombinant silkworm technology
  • Complete GMP-compliant manufacturing facilities
  • Specialized R&D organization
  • Stable operation of local production bases
  • Diverse product portfolio
  • Business expansion through key subsidiaries
  • Long-term trust relationships with customers
  • Rapid technical support system
  • Strengthened collaboration with research institutions
  • Specialized medical reagent market
  • Competitive edge in niche markets
  • Continuous investment in advanced production technologies
  • Stable capital base
  • Compact team of specialized experts

Competitive Advantages

  • Product differentiation through proprietary recombinant silkworm technology
  • High reliability and quality control of medical and research reagents
  • Stable supply via GMP-compliant manufacturing system
  • Advancement of diversification strategy through subsidiary collaboration
  • High expertise and brand power in the domestic market
  • Meticulous customer service with regional closeness
  • Application of technology from pharmaceutical to cosmetics raw materials
  • Product lineup expansion through advanced R&D capabilities
  • Rapid product development and market launch capabilities
  • Intellectual property backed by proprietary technologies
  • Strengthened market position in low-competition areas
  • Investment capacity from stable financial base
  • Niche leader specialized in medical reagent market
  • Customized responses to customer needs
  • Building of nationwide sales network

Threats

  • Intensifying competition in domestic and international pharmaceutical markets
  • Strengthened regulations on recombinant products
  • Profit pressure from rising R&D costs
  • Increasing entry by major pharmaceutical manufacturers
  • Demand fluctuation risks in overseas markets
  • Competitive disadvantage from delayed technological innovation
  • Price competition from new entrants
  • Raw material price instability
  • Litigation risks related to intellectual property rights
  • Production base risks from natural disasters, etc.
  • Challenges in talent acquisition
  • Market environment changes from emerging infectious diseases, etc.

Innovations

2023: Advanced Recombinant Silkworm Technology

Overview
Improved protein production technology using recombinant silkworms to enhance production efficiency.
Impact
Reduced production costs and improved product purity

2021: Development of New Antibody Reagents

Overview
Newly developed high-sensitivity and high-specificity antibody reagents for ELISA.
Impact
Improved diagnostic accuracy and expanded market share

2022: Expansion of GMP-Compliant Pilot Plant

Overview
Newly established pilot plant to strengthen manufacturing system and enhance quality control.
Impact
Improved product safety and expanded production capacity

2024: Renewal of Bio-Pharmaceutical Raw Material Production Line

Overview
Efficiency improvement and quality enhancement of raw material production line through introduction of latest equipment.
Impact
20% increase in production capacity and cost reduction

Sustainability

  • Reduction of environmental impact in manufacturing processes
  • Improved waste recycling rate
  • Introduction of energy-efficient equipment
  • Support for environmental education in local communities
  • Development of sustainable bio-materials